Safe Pro Joins with Other Firms in Private Placement
Safe Pro Group Inc. (NASDAQ: SPAI), a leader in artificial intelligence (AI)-powered defense and security solutions, today announced that it has entered into definitive agreements for a private placement with strategic investors including Ondas Holdings Inc. (NASDAQ: ONDS) and Unusual Machines Inc. (NYSE: UMAC), two leaders in the U.S. drone industry.
The private placement consists of the sale of 2,000,000 shares of common stock at a price of $4.00 per share and warrants to purchase 2,000,000 shares of common stock at an exercise price of $6.00 per share, for a potential investment package of up to $20 million. The investment is expected to provide the financial strength and strategic relationships to accelerate commercialization of Safe Pro’s patented AI technologies, including its Safe Pro Object Threat Detection (SPOTD) and newly developed Navigation Observation Detection Engine (NODE). The closing of the offering is expected to occur on or about August 20, subject to the satisfaction of customary closing conditions.
Safe Pro’s patented platform has already been recognized by the U.S. Army and is positioned to capitalize on the Senate Appropriations Committee’s proposed $617 million increase in funding for small, unmanned aircraft systems (SUAS), as well as the recently passed One Big Beautiful Bill Act (OBBBA) which allocates up to $30 billion in new drone and AI spending.
SPAI shares leapfrogged 57 cents, or 15.1%, to $4.35, while those for ONDS dipped six cents, or 1.5%, to $3.54, and shares in UMAC took ion 22 cents, or 2.3%, to $9.97.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


